Kyrgyzstan Medical Device Registration: Statutory Timelines of 50 and 30 Calendar Days Explained
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The statutory timelines of the Kyrgyzstan national registration procedure start from confirmation of fee payment. The standard procedure allows a maximum of 50 calendar days from the date payment is confirmed; for devices holding registration documents from one of the eight jurisdictions including the EU, the US and Japan, the simplified channel allows a maximum of 30 calendar days from the date payment is confirmed (a 2026 draft amendment by the responsible authority would compress this to 10 working days, not yet in force). Neither figure includes the completeness check before payment, the payment period, the deficiency response period, or the manufacturing site inspection period. Treating either number as the total project duration is the main source of scheduling errors.
2. Legal basis
- Cabinet Resolution No. 513, August 27, 2024, Annex 1, titled Procedures for National Registration, Expertise of Safety, Quality and Efficacy, Maintenance of the National Register and Nomenclature, Changes to Registration Files, and Suspension or Revocation of Registration Certificates.
- Statement of current timelines in the draft amendment released for public consultation by the Ministry of Health of the Kyrgyz Republic in 2026 (to amend Cabinet Resolution No. 513):
- Current rule: registration of devices holding certificates from the eight jurisdictions takes a maximum of 30 calendar days (from confirmation of fee payment);
- Current rule: the standard procedure takes a maximum of 50 calendar days (from confirmation of fee payment);
- Proposed change: the eight-jurisdiction channel would be compressed to 10 working days;
- Proposed mechanism: compression through merging the dossier completeness check and the issuance of the payment invoice, and accelerating decision approval and entry into the national register;
- Draft status, not yet in force.
- Article 2 of Annex 1 to Cabinet Resolution No. 513: definitions of verification and validation.
- Multilateral organization country study report (Japan International Cooperation Agency, November 2025): from document submission to certificate issuance takes 2 to 6 months.
Source note: the day-by-day breakdown of each review stage in Annex 1 to Resolution No. 513 could not be quoted verbatim from an official original in this verification round. The figures of 50 calendar days and 30 calendar days above come from the responsible authority’s description of current practice in the explanatory materials of the 2026 draft amendment, and reflect the current practical estimate; the source level should be noted when citing them.
3. Expert insights
Insight one: the trigger point is confirmation of payment, not submission of the application.
This design places payment ahead of the review. Three practical layers follow. First, the payment invoice is issued by the competent authority, and the timing of issuance depends on the progress of the completeness check. Second, the review clock does not start until payment is completed. Third, failure to pay within the prescribed period is a statutory ground for refusing registration. When the payment invoice can actually be obtained therefore determines the true starting line of the project.
Insight two: 50 calendar days is not 50 days of review; it is 50 days for the entire main process.
The 50 calendar days cover the main process from confirmation of payment to issuance of the certificate, including the two major stages of analytical expertise and specialized expertise. The analytical expertise covers technical testing, biological effects evaluation and verification of the reproducibility of analytical procedures; the specialized expertise delivers the scientific assessment of safety, efficacy and the benefit-risk ratio. The two stages run in series, and any supplementary request in either stage consumes the same 50 days.
Insight three: the compression levers in the draft expose where the current process loses time.
The three levers named in the draft explanation, merging the completeness check with invoice issuance, accelerating decision approval, and accelerating entry into the national register, correspond exactly to three waiting points in the current process. All three sit outside the expert review itself. This indicates that a substantial share of the actual elapsed time in the current process is consumed by administrative handoffs outside the review rather than by expert assessment. This conclusion has direct scheduling value for companies: shortening the administrative waiting periods, for example by paying immediately once the invoice is issued, is the only timeline lever fully controllable at project level.
Insight four: the 2-to-6-month range from the multilateral study does not contradict the statutory 50 days.
The Japan International Cooperation Agency country study of November 2025 states that from document submission to certificate issuance takes 2 to 6 months. This range is longer than the statutory 50 days because it includes the time between submission and confirmation of payment, deficiency response time, and possible inspection time. The two numbers measure different intervals: the 50 calendar days measure the main process after payment, while 2 to 6 months measure the full project cycle. We recommend that companies keep these two practical estimate bases explicitly separated in all external communication.
4. Practical recommendations
First, build the schedule as 50 days plus three buffers. The recommended project formula is: pre-payment preparation period + 50 calendar days + deficiency response buffer + inspection period (if required). Estimate each segment separately and never collapse them into a single number.
Second, compress the waiting time in the payment stage. Paying immediately after the invoice is issued and confirming receipt is the time lever fully controllable at project level. Pre-position the payment process and payment authorization with the authorized representative so that internal approval chains do not consume the clock.
Third, prepare deficiency responses as one-shot, complete answers. The deficiency response period is excluded from the statutory timeline but materially extends the project. After receiving a deficiency request, convene a joint assessment of technical and regulatory staff and answer completely in one round, avoiding a second deficiency cycle.
Fourth, keep scheduling simplified-channel projects at 30 calendar days. The proposed 10 working days is not yet in force. Use the current 30 calendar days as the baseline and treat the draft taking effect as an optimization scenario; never promise customers the shorter figure first.
5. Verification checklist
- □ Confirm the trigger point is confirmation of fee payment, not application submission;
- □ The project schedule formula contains four segments: pre-payment preparation + 50 calendar days + deficiency response buffer + inspection period (if required);
- □ Simplified-channel projects are baselined on the current maximum of 30 calendar days, with the draft 10 working days used only as an upside scenario;
- □ Payment process and payment authorization are pre-positioned with the authorized representative to compress waiting in the payment stage;
- □ A joint deficiency assessment mechanism (technical plus regulatory) is in place to achieve one-shot complete answers;
- □ External communication separates the two practical estimate bases: the statutory 50 calendar days (main process after payment) versus the full project cycle (multilateral estimate of 2 to 6 months).
Regulatory information verified as of October 29, 2026.
Our services cover: premarket pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and vigilance system setup, import and distribution compliance, fee estimation and project budget management.
GRZAN provides regulatory registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives, covering the full pathway from route selection to post-market obligations.
The GRZAN regulatory team consists of professionals with years of hands-on experience in Eurasian Economic Union registrations and maintains a stable local collaboration network in Bishkek, Almaty, Tashkent, Moscow and other cities, working in Chinese, Russian and English. We deliver actionable solutions for the issues foreign manufacturers most often encounter in the CIS region, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.
We hold to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are labeled as a practical estimate, and experience-based values are never presented as legal requirements.
For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, contact us at info@grzanglobal.com.
GRZAN | Global Medical Device Regulatory Registration and Compliance Services
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us